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Abstract: Human immunodeficiency virus-1 infection of the central nervous system is an early 
event after primary infection, resulting in motor and cognitive defects in a significant number 
of individuals despite successful antiretroviral therapy. The pathology of the infected brain is 
characterized by enhanced leukocyte infiltration, microglial activation and nodules, aberrant 
expression of inflammatory factors, neuronal dysregulation and loss, and blood–brain barrier 
disruption. Months to years following the primary infection, these central nervous system insults 
result in a spectrum of motor and cognitive dysfunction, ranging from mild impairment to frank 
dementia. The mechanisms that mediate impairment are still not fully defined. In this review 
we discuss the cellular and molecular mechanisms that facilitate impairment and new data 
that implicate intercellular communication systems, gap junctions and tunneling nanotubes, as 
mediators of human immunodeficiency virus-1 toxicity and infection within the central nervous 
system. These data suggest potential targets for novel therapeutics.
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Introduction
Human immunodeficiency virus-1 (HIV) infection has expanded into a global health 
pandemic since the first cases were described in 1981, having infected an estimated 
33 million people worldwide (UNAIDS, 2008). In the early 1990s, the development of 
antiretroviral therapy changed the face of the disease. In the developed world, HIV went 
from causing a fatal disease to being a chronic infection because viral loads are frequently 
undetectable and CD4 counts are restored to near normal levels in most individuals on 
antiretroviral therapy. However, the viral reservoirs that persist in infected individuals 
are not eradicated and, because people live longer with HIV , the virus continues to cause 
damage despite low viral replication. A predominant clinical consequence of HIV that 
persists despite treatment is its neurological effects, which are collectively referred to as 
HIV-associated neurocognitive disorders (HAND) and occur in approximately 50% of 
infected individuals.1 Because HIV infected people on antiretroviral therapy live longer, 
the prevalence of cognitive and motor dysfunction is increasing.2,3 Thus, the need for 
effective central nervous system (CNS)-targeted therapeutics is becoming even more 
important. The mechanisms of HIV infection in the CNS remain incompletely character-
ized and it is likely that many therapeutic targets have yet to be identified.
Clinical consequences of HIV infection in the CNS
The clinical features of HAND are both subcortical and cortical, and individuals 
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  manifestations are divided into three major groups: 
  asymptomatic neurocognitive impairment, mild neurocogni-
tive disorder, and HIV-associated dementia.4 Asymptomatic 
neurocognitive impairment is defined by performance at 
least one standard deviation below the mean in at least two 
cognitive areas with no impairment in activities of daily 
living, mild neurocognitive disorder is performance at least 
one standard deviation below the mean in at least two cogni-
tive areas with mild to moderate impairment in activities of 
daily living, and HIV-associated dementia is performance at 
least two standard deviations below the mean in at least two 
cognitive areas with severe impairment in activities of daily 
living.4 Before antiretroviral therapy, over 15% of late stage 
HIV-infected individuals developed HIV-associated dementia 
and 50% of infected individuals developed some form of 
HAND.1 Now, the number with HIV-associated dementia has 
decreased to less than 5%, but the percentage of individuals 
with mild neurocognitive disorder has remained at 20%, and 
the percentage with asymptomatic neurocognitive impair-
ment has increased to 25%.1 Thus, 50% of HIV-infected 
individuals still develop HAND.1
HAND results in a triad of cognitive, behavioral 
and motor dysfunction and its progression is often not 
  unidirectional. HIV-infected individuals may progress to 
asymptomatic neurocognitive impairment, then mild neuro-
cognitive disorder, then HIV-associated dementia, but they 
can also fluctuate between these forms or go into remis-
sion. Diagnosis of HAND is based on neuropsychological 
testing, neuroimaging, and exclusion of delirium or any 
CNS opportunistic infections or other cause of dementia 
as the reason for the neurocognitive impairment.4,5 For 
diagnosis, neuropsychological testing must include the 
following domains: verbal/language, attention/working 
memory, abstraction/executive, memory (learning/recall), 
speed of information processing, sensory-perceptual, and 
motor skills.4 The standard of neuroimaging is magnetic 
resonance imaging, which demonstrates cerebral atrophy 
and ventricular enlargement in impaired individuals, but 
there is ongoing work to develop better imaging tools for 
diagnosis of HAND.5–7
HIV neuropathology
Soon after infection, as early as 15 days,8 HIV enters the CNS 
in the majority of, if not all, infected individuals. Viral entry 
into the CNS is believed to be mediated through a “Trojan 
horse” mechanism, whereby HIV-infected monocytes cross 
the blood–brain barrier and then release virus into the CNS. 
HIV released from these infected cells then causes infection 
in the brain that results in significant inflammation and even-
tually neuronal damage and loss.
HIV primarily infects CNS macrophages and microglia 
and can infect astrocytes at low levels.9–13 There is little 
evidence for HIV infection of oligodendrocytes and neu-
rons. However, significant neuronal dysfunction, including 
axonal and dendritic pruning, is prevalent throughout the 
CNS.14–18 This results from the inflammatory factors and 
neurotoxic substances released by infected as well as acti-
vated, uninfected cells. HAND pathology is characterized by 
multinucleated giant cells, microglial nodules, gliosis, myelin 
pallor, and neuronal loss, demonstrating the significant role 
of immune cells and subsequent damage to neurons in the 
pathogenesis of this disease.
Mechanisms of HIV entry into  
the CNS and infection of CNS cells
As discussed above, the predominant means of HIV entry 
into the CNS is through a “Trojan horse” mechanism by 
which infected monocytes cross the blood–brain barrier and 
release virus within the CNS that can then infect resident cells 
(Figure 1). Other proposed mechanisms include direct infection 
of cells that comprise the blood–brain barrier, endothelial cells 
and astrocytes, and transfer via these cells from the periphery 
to the CNS,19–21 or direct extracellular movement of the virus 
across a disrupted blood–brain barrier.22 While it is important 
to consider these mechanisms, they are less well characterized, 
and are likely minor contributors to CNS infection.
Under physiological conditions, leukocyte transmi-
gration across the blood–brain barrier into the CNS 
parenchyma is a restricted and highly regulated process that 
requires cell- and tissue-specific mechanisms of leukocyte-
endothelial interactions. These interactions involve a variety 
of intracellular and extracellular molecules, including 
chemokines, cytokines and their receptors, cell adhesion 
molecules, tight junctions, and adherens junction proteins 
on brain microvascular endothelial cells and leukocytes. 
Aberrant expression of chemokines and their receptors, adhe-
sion molecules, and matrix metalloproteinases in the context 
of HIV contribute to the transmigration of leukocytes across 
the blood–brain barrier, exacerbated CNS inflammation, and 
HIV replication within the brain (see Figure 1).22
Chemokines are important mediators of transmigration of 
leukocytes across the blood–brain barrier. Chemokines play 
a crucial role in the pathogenesis of HAND because they 
facilitate leukocyte transmigration and direct movement of 
resident cells, such as microglia/macrophages. Expression 
of chemokines and their receptors is dysregulated in HIV HIV/AIDS - Research and Palliative Care 2010:2 41
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and simian immunodeficiency virus encephalitic brains 
in comparison with normal brains, as well as microglia/
macrophages, astrocytes, endothelial cells, and neurons 
exposed to HIV or soluble viral proteins.23–31 Chemokine (C-C 
motif) ligand 2 (CCL2) is the most potent chemoattractant 
chemokine for monocytes and activated T-cells.32–34 CCL2 
levels are elevated in the cerebrospinal fluid and brain tissue 
of individuals with HIV-associated dementia.28 Our group 
demonstrated that CCL2 plays a major role in inflammation as 
well as neuroprotection (see below) in the context of HAND. 
CCL2 is a critical chemokine in the transmigration of HIV-
infected monocytes and lymphocytes across the blood–brain 
barrier.31 We demonstrated that HIV infection of peripheral 
blood mononuclear cells (PBMCs) enhanced their transmi-
gration across an in vitro human blood–brain barrier model in 
response to CCL2.31 HIV-infected PBMCs also had increased 
expression of chemokine (C-C motif) receptor 2 (CCR2), 
the receptor for CCL2, which may facilitate this enhanced 
transmigration (see Figure 1).31 The increased transmigration 
of PBMCs across the blood–brain barrier was associated with 
blood–brain barrier disruption and was CCL2 specific, given 
that no increased transmigration of HIV-infected cells was 
found with CCL3, CCL4, or CCL5.31
In addition to CCR2, previous reports showed enhanced 
expression of the chemokine receptors CXCR4 and CCR5 on 
HIV-infected T-cells,35,36 suggesting that HIV infection alters 
the expression of chemokine receptors to facilitate invasion as 
well as infection. Another chemokine, fractalkine (CX3CL1), 
has been associated with enhanced transendothelial migra-
tion of CD16+ monocytes under normal and inflammatory 
conditions and endothelial cells expressing fractalkine trigger 
CD16+ monocytes to produce CCL2, interleukin-6 (IL-6) 
and matrix metalloproteinase-9 (MMP-9).37,38 The role of 
fractalkine in transmigration of HIV-infected monocytes has 
not yet been examined.
In addition to upregulating chemokine receptors and 
perhaps enhancing the response to chemotactic agents, HIV 
infection of leukocytes also alters the expression of a number 
of adhesion molecules that likely facilitate transmigration of 
HIV-infected cells across the blood–brain barrier. It has been 
demonstrated in vivo that HIV infection of human monocytes 
increases expression of lymphocyte function-associated 
antigen-1 (LFA-1).39,40 HIV-infected monocytes in contact 
with endothelial cells induce the expression of E-selectin 
and vascular cell adhesion molecule-1 (VCAM-1).41 An 
immunohistochemical examination of HIV encephalitic tis-
sue showed increased expression of intercellular adhesion 
molecule-1 (ICAM-1) and VCAM-1 on endothelial cells and 
astrocytes.42 We found that platelet/endothelial cell adhesion 
molecule-1 (PECAM-1) expression is dysregulated in HIV-
infected primary human PBMCs.43 Normally, PECAM-1 
is concentrated at sites of cell contact and antibodies 
blocking the extracellular portion of PECAM-1 selectively 
reduce diapedesis, but not adhesion or cell activation, of 
  uninfected monocytes.44 Thus, homophilic interactions 
between PECAM-1 proteins expressed on monocytes and 
on endothelial cells are critical for diapedesis through 
interendothelial junctions. We showed that HIV-infected 
PBMCs shed soluble PECAM-1 (sPECAM-1) in the pres-
ence of the chemokine CCL2.43 Using post mortem tissue 
from individuals with HIV-associated dementia, we found 
an accumulation of sPECAM-1 within the CNS.43 We also 
showed that CCL2 increases PECAM-1 on the surface of 
brain microvascular endothelial cells (unpublished data from 
Roberts et al). Increased serum levels of sPECAM-1 were 
detected in individuals with multiple sclerosis and HIV, 
43,45 suggesting a role for the soluble form of this adhesion 
molecule in CNS inflammation. We propose that sPECAM-1 
competes for the homotypic PECAM-1 interaction between 
two endothelial cells, which results in destabilization of these 
interactions with subsequent blood–brain barrier disruption 
and enhanced transmigration.
These findings support the hypothesis that HIV enters 
the brain by the transmigration of HIV-infected monocytes 
across the blood–brain barrier in response to chemokine 
gradients. HIV infection enhances the expression of specific 
chemokine receptors on the surface of infected leukocytes, 
enabling the detection of lower amounts of these chemokines 
and resulting in leukocyte activation and transmigration into 
the brain. HIV also increases the expression of a number of 
adhesion molecules, which facilitate binding and diapedesis 
across the blood–brain barrier.
CNS damage by viral and immune 
factors
While HIV is able to infect CNS macrophages, microglia, 
and astrocytes, as well as causing neuronal dysfunction and 
loss, there is little evidence to suggest that the virus infects 
neurons. Therefore, it is believed that infected cells release 
factors including viral proteins, particularly gp120 and tat, 
which are toxic to neurons (Figure 1).
Gp120 is the envelope surface protein of HIV and can bind 
CXCR4 and CCR5, even in the absence of CD4, on the surface 
of neurons and trigger neuronal apoptosis.46–48 The majority of 
brain-derived viruses are R5 (binding to CCR5),49 however, 
X4 (binding to CXCR4) viruses, which are found in the brain HIV/AIDS - Research and Palliative Care 2010:2 42
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late in the course of disease, or X4 gp120, induce the highest 
levels of neuronal cell death.50 This may contribute to the 
more severe forms of HAND that manifest late in disease 
progression. Specific mutations in the V1 and V3 gp120 
loops have been identified in individuals with or without HIV-
associated dementia, suggesting adaptation of the virus to the 
brain through changes in gp120.51–53 Gp120 can be detected 
in the brain of HIV-infected individuals, colocalizing with 
microglia/macrophages, microglial nodules, and multinucle-
ated giant cells.54 Post-transcriptional changes in the V3 or 
V4 regions of gp120 that alter sequence or glycosylation may 
determine the course of disease as they have been correlated 
with the incidence of HIV-associated dementia.55,56 Treatment 
of macrophages or microglia with recombinant gp120 results 
in the release of many cytokines and chemokines, including 
tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), 
IL-6, CCL2, macrophage inflammatory proteins (MIPs), and 
CCL5, all of which may participate in the neuroinflammation 
that is also damaging to neurons.57–60
Tat, the transactivator of transcription of HIV , is released 
from infected cells and can be found in the serum and brain 
tissue of individuals with HIV encephalitis.61–67 Tat is tran-
scribed and released from cells even when HIV replication 
is controlled by antiretroviral therapy because HIV integrates 
into the host genome.63 Tat interacts with a number of cell 
surface receptors, including integrins, a vascular endothelial 
growth factor (VEGF) receptor, and low density lipoprotein 
receptor-related protein-1 (LRP-1).68–70 Tat induces release 
of cytokines and chemokines from microglia, macrophages, 
neurons, and astrocytes in the CNS and causes disruption of 
the blood–brain barrier.71–73 In addition to these inflamma-
tory effects, tat causes significant neurotoxicity in a variety 
of systems.74–83
The mechanisms that result in tat-induced neuronal 
apoptosis are still under investigation, but it is clear that 
glutamate receptors, such as the N-methyl-D-aspartate 
receptor (NMDAR), participate in the process.72,82–86 Our 
group demonstrated that tat treatment of mixed cultures of 
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Figure 1 Mechanisms of HIV-mediated CNS damage. HIV infection of peripheral blood mononuclear cells, particularly monocytes, leads to enhanced expression of adhe-
sion molecules and chemokine receptors such as CCR2. This results in increased transmigration of infected cells. HIV enters the CNS through a “Trojan horse” mechanism, 
crossing the blood–brain barrier, formed by endothelial cells and astrocyte end feet, within infected monocytes. Once inside the CNS, infected monocytes can differentiate 
into macrophages and secrete a number of inflammatory mediators, particularly chemokines such as CCL2 that further enhance transmigration of immune cells across the 
blood–brain barrier. HIV infection of macrophages increases the numbers of TNT that connect with other macrophages. HIV or HIV proteins may travel within or on TNT, 
facilitating viral spread. Infected cells also secrete viral proteins such as gp120 and tat that are toxic to neurons. HIV can infect astrocytes at low levels. Infected astrocytes 
transfer signals to neighboring uninfected astrocytes and neurons. These signals are transferred through gap junctions and result in apoptosis (X) in both astrocytes and neu-
rons. Astrocytes are necessary for the metabolic maintenance of neurons. Thus, the astrocyte loss and dysfunction that occurs with HIV infection also results in metabolic 
dysregulation and neuronal toxicity.
Abbreviations: CNS, central nervous system; EC, endothelial cells; HIV, human immunodeficiency virus; TNT, tunneling nanotubes.HIV/AIDS - Research and Palliative Care 2010:2 43
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primary human fetal neurons and astrocytes causes apoptosis 
in both cell types.82,83 This apoptosis is mediated by early 
formation of a complex involving the NMDAR, LRP-1, post-
synaptic density protein of 95 kDa (PSD-95), and neuronal 
nitric oxide synthase.83 This complex results in activation of 
the NMDAR and subsequent Ca2+ influx. Increased intracel-
lular Ca2+ activates neuronal nitric oxide synthase and results 
in nitric oxide production and diffusion.83 Blocking neuronal 
nitric oxide synthase activity inhibits apoptosis in neurons, 
and blocking all forms of nitric oxide synthase inhibits 
apoptosis in neurons and astrocytes, which suggests that 
nitric oxide is the key mediator of tat-induced apoptosis.83 In 
addition, we showed that two components of the complex, 
NMDAR and LRP, are critical to tat-induced apoptosis. 
Treatment with MK801, a noncompetitive NMDAR antago-
nist, or with receptor associated protein (RAP), a competi-
tive antagonist of LRP, inhibits tat-induced apoptosis in all 
neurons and astrocytes.82,83
LRP and its ligands, particularly apolipoprotein E4 
(ApoE4), are known to be involved in Alzheimer’s disease, 
suggesting a potential link between the mechanisms of 
Alzheimer’s disease and HAND. Polymorphisms in ApoE4 
are associated with poor prognoses in a number of neuro-
logical disorders, including Alzheimer’s disease, stroke, 
hemorrhage, and trauma.87–90 It is possible that tat toxicity and 
ApoE may have similar or overlapping signaling pathways 
involving activation of LRP, NMDAR, synaptic scaffold 
proteins, glutamate, and nitric oxide production. Consistent 
with this hypothesis, it has been demonstrated that ApoE 
alleles are important predictors for accelerated dementia in 
HIV-infected individuals and may help predict their disease 
course.91,92 Thus, we suggest that LRP may play a significant 
role in the development of HAND and may be a potential 
target for therapeutics.
Inflammation is a hallmark of HAND and mediates the 
CNS damage in neurocognitively impaired HIV-infected 
individuals; however, some aspects of this inflammation may 
actually be neuroprotective. Several inflammatory cytokines 
have been reported to be elevated in the CNS and/or cere-
brospinal fluid of individuals with HAND, including TNF-α, 
IL-1β, IL-6, and granulocyte macrophage-colony stimulating 
factor.93–95 These cytokines may be produced by HIV-infected 
perivascular macrophages, infiltrated leukocytes, resident 
microglial cells, endothelial cells, and astrocytes.96 TNF-α 
upregulates HIV replication and also synergizes with IL-6 
and IL-2 to cause reactivation of latent virus.97 However, 
TNF-α also appears to have neuroprotective properties 
by increasing NF-κB (nuclear factor kappa-light-chain 
enhancer of activated B-cells) activity and altering calcium 
and potassium levels and bcl-2 expression.98 CCL2 can also 
be neuroprotective. We showed that when mixed cultures 
of neurons and astrocytes were treated with tat and CCL2 
concomitantly, CCL2 inhibits tat-induced apoptosis.82 When 
we treat with CCL2 two hours after tat, this inhibitory effect 
is lost, indicating that CCL2 interferes with the early effects 
of tat. In fact, CCL2 inhibits formation of the complex 
between NMDAR, LRP-1, PSD-95, and neuronal nitric oxide 
synthase and inhibits nitric oxide production.83 These data 
indicate that TNF-α and CCL2 have a dual role within the 
CNS, suggesting that the actions of these molecules depend 
on the time frame of their secretion and their microenviron-
ment. Furthermore, due to this dual role, therapies targeting 
either molecule should be approached cautiously.
Intercellular communication 
systems amplify CNS damage
Our laboratory was one of the first to examine the role of 
intercellular communication in the context of HAND. We 
demonstrated that gap junctions and tunneling nanotubes 
(TNT) each play a role in neuroinflammation through direct 
transfer of mediators between the cytoplasm of connected 
cells.9,99
TNT and gap junctions are the only described communi-
cation systems that facilitate exchange of cytoplasmic factors 
through direct contact between the cytoplasm of connected 
cells. TNT and gap junctions coordinate important biological 
processes such as development, metabolism, homeostasis, 
and the immune response.100–105 The major difference between 
TNT and gap junctions is the distance between connected 
cells and the sizes of the molecules transferred. TNT facili-
tate long-range communication through extended processes, 
while gap junctions require direct cell-to-cell contact for their 
formation. Gap junctions and TNT both traffic small mol-
ecules, but gap junctions have a size limit of 1.2 kDa, while 
TNT can also transfer organelles and vesicles.101,105
Gap junctions are channels formed by connexins, a family 
of proteins with over 21 members in humans.106 Six connexins 
form a single connexon (hemichannel) and two connexons 
from apposing cells form a gap junction.105,107 Connexons can 
be formed by one (homotypic) or several (heterotypic) types 
of connexins, and gap junctions are formed by two identi-
cal (homotypic) or different (heterotypic) connexons. This 
variation generates connexons and gap junctions that differ 
in their biophysical properties and permeability.108 The pore 
that is formed has a large internal diameter, approximately 
12 Å, that enables ions and intracellular messengers less than HIV/AIDS - Research and Palliative Care 2010:2 44
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1.2 kDa to diffuse between connected cells. Molecules that 
are transferred through these channels include inositol tri-
phosphate (IP3), calcium, cyclic nucleotides, metabolites, 
toxic substances such as cytochrome c, neurotransmitters, 
and viral peptides.105,109 Through the diffusion of these second 
messengers, gap junctions coordinate physiological processes 
such as development, differentiation, neuronal synchrony, 
inflammation, survival, apoptosis, metabolism, cell contrac-
tion, and signaling.105 In pathologic conditions, it has been 
proposed that gap junctions participate in cell survival and/or 
apoptosis and facilitate clearance of pathogens, but the extent 
of gap junction involvement is not fully characterized.
We demonstrated that gap junctions in astrocytes are criti-
cal for the transfer of an apoptotic signal from HIV-infected 
astrocytes to uninfected astrocytes and neurons.9 Astrocytes 
are key cells in the CNS that regulate CNS differentiation, 
neuronal excitation, extracellular metabolites, synaptic 
plasticity, formation of scar tissue following neuronal loss, 
immune activation, blood–brain barrier integrity, and gly-
cogen storage.110,111 Our data indicate that, although only a 
small percentage of cultured primary human fetal astrocytes 
are infected by HIV , these cells transmit toxic signals through 
gap junctions to neighboring cells, particularly uninfected 
astrocytes and neurons, that result in apoptosis (Figure 1).9 
We also demonstrated that gap junctions control glutamate 
metabolism and secretion of CCL2, suggesting a critical role 
in maintenance of neuronal function and in CNS inflam-
mation.9 Taken in combination, these results indicate that 
further investigation of HIV infection of astrocytes and its 
role in HAND is required despite the low level of produc-
tive infection.
We demonstrated a role for gap junctions in the transmi-
gration of PBMCs across the blood–brain barrier.112 PBMCs 
normally do not express connexins. However, in inflammatory 
conditions, connexin 43 (Cx43) expression can be induced.112,113 
Our data indicate that lipopolysaccharide (LPS) or TNF-α 
and interferon-γ (IFN-γ) treatment induce Cx43 expression in 
monocytes.112 These cells migrate across an in vitro model of 
the blood–brain barrier in response to CCL2 and we observed 
Cx43 staining in monocytes, astrocytes, and endothelial cells 
that localized to the sites of heterocellular contact.112 Gap 
junctions were important for the transmigration of treated 
monocytes because the gap junction blockers octanol and 
18-α-glycerrhetinic acid significantly decreased transmigra-
tion.112 Based on our findings, we propose that gap junctions 
may play an important role in the pathogenesis of HAND by 
mediating infected astrocyte-induced toxicity as well as trans-
migration of monocytes across the blood–brain barrier.
TNT form an active communication system that enables 
neighboring cells to exchange organelles and vesicles, and 
to coordinate signaling over relatively long distances. In 
pathologic conditions, these cytoplasmic bridges allow bac-
teria and viruses to travel between connected cells without 
being exposed to the immune cell surfaces or extracellular 
antimicrobial factors.102–104,114–118 TNT formation has been 
described in immune cells, including B-cells, T-cells, natural 
killer cells, neutrophils and monocytes, as well as neuronal 
and glial cells.101 The mechanisms that facilitate TNT forma-
tion remain unclear, however a recent study demonstrated 
that a mammalian protein, M-Sec, induces formation of 
membrane protrusions that attach to neighboring cells and 
result in formation of TNT-like structures.119 Our laboratory 
demonstrated that primary human macrophages infected 
with HIV have greater numbers of TNT, suggesting that 
HIV induces the expression or stability of these processes.99 
Furthermore, the HIV capsid protein p24 colocalizes with 
TNT, suggesting that viral spread may occur through this 
mechanism (Figure 1).99 Recently, it was demonstrated that 
HIV evades IgG2 and IgA responses by transferring the viral 
immunosuppressive protein Nef from infected macrophages 
to B-cells via TNT, decreasing B-cell response to IgG2 and 
IgA inducing signals from CD4+ T-cells.120
We propose that intercellular communication mediated 
by gap junctions and TNT enhances cellular dysfunction and 
toxicity, inflammation, and HIV infection. An understanding 
of their role in HAND may indicate useful therapeutic targets 
to limit the neuropathogenesis of HIV .
Potential therapeutics
The development of successful antiretroviral therapy has 
significantly reduced the percentage of HIV-infected indi-
viduals who develop HIV-associated dementia; however, the 
percentage of individuals who are neurocognitively impaired 
has remained unchanged. This is due, in large part, to the fact 
that many of the antiretrovirals in use do not have adequate 
CNS penetration. Thus, although the systemic infection 
is well controlled, CNS infection persists. In addition to 
promoting an emphasis on CNS-penetrating antiretroviral 
therapy, a number of ongoing studies are working to develop 
successful adjunctive therapies to combat HAND. Some 
have examined ways to improve drug delivery to the CNS, 
including the use of nanoparticles121,122 and intranasal delivery 
of medications.123 Other studies have largely targeted the 
immune response or neuronal damage.
Oxidizing agents are a well demonstrated component 
of neurotoxicity and inflammation in HIV-associated CNS HIV/AIDS - Research and Palliative Care 2010:2 45
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disease and a number of studies focused on using antioxidant 
agents to reduce neuronal damage and loss. One therapy that 
has been tested in clinical trials is selegiline, which inhibits 
monoamine oxidase B, resulting in decreased free radicals, 
increased superoxide dismutase and catalase, and increasing 
the synthesis of neurotrophic factors.124–128 A selegiline trans-
dermal system was developed and has been tested in a number 
of Phase II clinical trials. While two trials found improvement 
in psychomotor speed,129,130 two more recent trials did not 
find any difference in cognitive or functional outcome and 
no effect on brain metabolites or levels of markers of oxida-
tive stress, suggesting that the selegiline transdermal system 
may not be clinically useful for the treatment of HAND.131,132 
Another potential antioxidant therapy is a gene therapy system 
to deliver superoxide dismutase or glutathione peroxidase to 
neurons, which has been shown to decrease gp120-induced 
neuronal apoptosis in culture and in the caudate putamen 
and substantia nigra of mice.133–135 When both superoxide 
dismutase and glutathione peroxidase were delivered together, 
this also decreased tat-induced neuronal apoptosis.136
Inflammation is one of the hallmarks of HAND, and 
therapies to target this inflammation could potentially ame-
liorate the CNS consequences of HIV. Minocycline is a 
tetracycline derivative that has been in use since the 1960s 
for the treatment of bacterial infections. Minocycline can 
also be used for the treatment of inflammatory conditions, 
and recent studies showed that it can cross the blood–brain 
barrier and be neuroprotective.137–139 There are a number of 
ongoing clinical trials testing the efficacy of minocycline 
in the treatment of neurological diseases. In the context 
of HAND, minocycline was demonstrated to reduce the 
incidence and severity of encephalitis in simian immuno-
deficiency virus-infected macaques and a Phase II clinical 
trial is underway at the National Institute of Allergy and 
Infectious Diseases in the US, as well as a clinical trial in 
Uganda to determine whether it reduces cognitive deficits 
in HIV-infected individuals.140,141
Our group and others demonstrated the importance of the 
NMDAR in HIV-induced neurotoxicity. Memantine, a non-
competitive NMDAR antagonist, is in use in Europe for the 
treatment of Alzheimer’s disease and Parkinson’s disease 
and has recently been approved in the US for Alzheimer’s 
disease treatment.142–147 Memantine prevents gp120, tat, and 
platelet-activating factor neurotoxicity in cell culture and is 
neuroprotective in mouse models of HAND.148–151 A recent 
Phase II clinical trial of memantine in cognitively impaired 
HIV-infected adults found no significant improvement in cog-
nitive dysfunction over a period of 16 weeks, but individuals 
treated with memantine did have an improvement in brain 
metabolism, as measured by N-acetyl aspartate to creatinine 
ratio using proton magnetic resonance spectroscopy.152 This 
study suggested that memantine may be an effective treat-
ment for HAND, and that longer term trials are necessary to 
determine its efficacy.
While there are some promising therapies currently in 
trial targeting some of the mechanisms of HIV-mediated CNS 
damage discussed in this review, there is still no definitive 
treatment for the neurocognitive dysfunction that occurs in 
up to 50% of infected individuals. It is important to continue 
investigation of new avenues for potential therapies.
Our recent work with gap junctions and TNT suggests a 
role for intercellular communication in the neuropathogenesis 
of HIV and may provide novel targets for therapeutics. We 
propose that TNT may provide an alternate route for HIV 
spread in addition to the well characterized receptor-mediated 
entry. This pathway may not be affected by extracellular 
antiretroviral therapy and may contribute to the persistence 
of viral reservoirs. Thus, an understanding of the mechanisms 
that participate in the formation of TNT and transport of virus 
or viral proteins through TNT may lead to identification of 
therapeutic targets to block intracellular viral spread.
We also demonstrated that gap junctions facilitate transfer 
of an apoptotic signal from astrocytes to neighboring cells, 
which likely contributes to the cellular dysfunction and cell 
death in the CNS of HIV infected individuals. Gap junctions 
play vital roles in electrical and metabolic coordination within 
the CNS. Thus, it is unlikely that blocking gap junction chan-
nels would be a useful therapeutic approach. However, this 
work demonstrates the importance of the small population 
of infected astrocytes in the development of HAND. Thus, 
by understanding the mechanisms of this infection, we can 
begin to determine how to target this component of viral 
CNS infection therapeutically to eradicate this significant 
viral reservoir.
Acknowledgements
We are grateful to Dr. Brad Poulos and the Human Fetal 
Tissue Repository and the Analytical Imaging Facilities 
at the Albert Einstein College of Medicine. This work was 
supported by the National Institutes of Mental Health grants 
MH070297, MH075679, and MH083497 to JWB, NIH 
Centers for AIDS Research Grant AI-051519, a KO1 grant 
from the National Institutes of Mental Health (MH076679) 
to EAE, MSTP Training Grant 5 T32 GM007288 and the   
HIV-AIDS and Opportunistic Infections Institutional 
  Training Grant T32 AI-007501 to JEH.HIV/AIDS - Research and Palliative Care 2010:2 46
Hazleton et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Disclosures
The authors report no conflicts of interest in this work.
References
  1.  Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in 
the brain: neuronal injury and repair. Nature Reviews. 2007;8(1): 
33–44.
  2.  Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Influ-
ence of HAART on HIV-related CNS disease and neuroinflammation. 
J Neuropathol Exp Neurol. 2005;64(6):529–536.
  3.  McArthur JC, Haughey N, Gartner S, et al. Human immunodefi-
ciency virus-associated dementia: an evolving disease. J Neurovirol. 
2003;9(2):205–221.
  4.  Antinori A, Arendt G, Becker JT, et al. Updated research nosol-
ogy for HIV-associated neurocognitive disorders. Neurology. 
2007;69(18):1789–1799.
  5.  Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to 
HIV-1 infection. Semin Neurol. 2007;27(1):86–92.
  6.  Chang L, Tomasi D, Yakupov R, et al. Adaptation of the attention 
network in human immunodeficiency virus brain injury. Ann Neurol. 
2004;56(2):259–272.
  7.  Ances BM, Roc AC, Wang J, et al. Caudate blood flow and volume 
are reduced in HIV+ neurocognitively impaired patients. Neurology. 
2006;66(6):862–866.
  8.  Davis LE, Hjelle BL, Miller VE, et al. Early viral brain invasion 
in iatrogenic human immunodeficiency virus infection. Neurology. 
1992;42(9):1736–1739.
  9.  Eugenin EA, Berman JW. Gap junctions mediate human immu-
nodeficiency virus-bystander killing in astrocytes. J Neurosci. 
2007;27(47):12844–12850.
  10.  Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB. Cel-
lular localization of human immunodeficiency virus infection within 
the brains of acquired immune deficiency syndrome patients. Proc Natl 
Acad Sci U S A. 1986;83(18):7089–7093.
  11.  Conant K, Tornatore C, Atwood W, Meyers K, Traub R, Major EO. 
In vivo and in vitro infection of the astrocyte by HIV-1. Adv Neuroim-
munol. 1994;4(3):287–289.
  12.  Gorry PR, Ong C, Thorpe J, et al. Astrocyte infection by HIV-1: 
mechanisms of restricted virus replication, and role in the pathogenesis 
of HIV-1-associated dementia. Curr HIV Res. 2003;1(4):463–473.
  13.  Churchill MJ, Wesselingh SL, Cowley D, et al. Extensive astrocyte 
infection is prominent in human immunodeficiency virus-associated 
dementia. Ann Neurol. 2009;66(2):253–258.
  14.  James HJ, Sharer LR, Zhang Q, et al. Expression of caspase-3 in brains 
from paediatric patients with HIV-1 encephalitis. Neuropathol Appl 
Neurobiol. 1999;25(5):380–386.
  15.  Adle-Biassette H, Chretien F, Wingertsmann L, et al. Neuronal apop-
tosis does not correlate with dementia in HIV infection but is related to 
microglial activation and axonal damage. Neuropathol Appl Neurobiol. 
1999;25(2):123–133.
  16.  Giometto B, An SF, Groves M, et al. Accumulation of beta-amyloid 
precursor protein in HIV encephalitis: relationship with neuropsycho-
logical abnormalities. Ann Neurol. 1997;42(1):34–40.
  17.  An SF, Giometto B, Groves M, et al. Axonal damage revealed by 
accumulation of beta-APP in HIV-positive individuals without AIDS. 
J Neuropathol Exp Neurol. 1997;56(11):1262–1268.
  18.  Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a patho-
logical substrate for human immunodeficiency virus-related cognitive 
disorders. HNRC Group. The HIV Neurobehavioral Research Center. 
Ann Neurol. 1997;42(6):963–972.
  19.  Mankowski JL, Spelman JP, Ressetar HG, et al. Neurovirulent sim-
ian immunodeficiency virus replicates productively in endothelial 
cells of the central nervous system in vivo and in vitro. J Virol. 
1994;68(12):8202–8208.
  20.  Bobardt MD, Salmon P, Wang L, et al. Contribution of proteoglycans 
to human immunodeficiency virus type 1 brain invasion. J Virol. 
2004;78(12):6567–6584.
  21.  Argyris EG, Acheampong E, Nunnari G, Mukhtar M, Williams KJ, 
Pomerantz RJ. Human immunodeficiency virus type 1 enters primary 
human brain microvascular endothelial cells by a mechanism involv-
ing cell surface proteoglycans independent of lipid rafts. J Virol. 
2003;77(22):12140–12151.
  22.  Buckner CM, Luers AJ, Calderon TM, Eugenin EA, Berman JW. Neuro-
immunity and the blood–brain barrier: molecular regulation of leukocyte 
transmigration and viral entry into the nervous system with a focus on 
neuroAIDS. J Neuroimmune Pharmacol. 2006;1(2):160–181.
  23.  Albright AV, Shieh JT, Itoh T, et al. Microglia express CCR5, 
CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor 
for human immunodeficiency virus type 1 dementia isolates. J Virol. 
1999;73(1):205–213.
  24.  Lavi E, Kolson DL, Ulrich AM, Fu L, Gonzalez-Scarano F. Chemokine 
receptors in the human brain and their relationship to HIV infection. J 
Neurovirol. 1998;4(3):301–311.
  25.  Gabuzda D, He J, Ohagen A, Vallat AV. Chemokine receptors in 
HIV-1 infection of the central nervous system. Semin Immunol. 
1998;10(3):203–213.
  26.  McManus CM, Weidenheim K, Woodman SE, et al. Chemokine and 
chemokine-receptor expression in human glial elements: induction by 
the HIV protein, Tat, and chemokine autoregulation. Amer J Pathol. 
2000;156(4):1441–1453.
  27.  Conant K, Garzino-Demo A, Nath A, et al. Induction of monocyte 
chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation 
in AIDS dementia. Proc Natl Acad Sci U S A. 1998;95(6):3117–3121.
  28.  Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE. 
Beta-chemokines MCP-1 and RANTES are selectively increased in 
cerebrospinal fluid of patients with human immunodeficiency virus-
associated dementia. Ann Neurol. 1998;44(5):831–835.
  29.  Sanders VJ, Pittman CA, White MG, Wang G, Wiley CA, Achim 
CL. Chemokines and receptors in HIV encephalitis. AIDS (London, 
England). 1998;12(9):1021–1026.
  30.  Sasseville VG, Smith MM, Mackay CR, et al. Chemokine expression 
in simian immunodeficiency virus-induced AIDS encephalitis. Am J 
Pathol. 1996;149(5):1459–1467.
  31.  Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, 
Berman JW. CCL2/monocyte chemoattractant protein-1 mediates 
enhanced transmigration of human immunodeficiency virus (HIV)-
infected leukocytes across the blood–brain barrier: a potential 
mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci. 
2006;26(4):1098–1106.
  32.  Yla-Herttuala S, Lipton BA, Rosenfeld ME, et al. Expression of 
monocyte chemoattractant protein 1 in macrophage-rich areas of 
human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A. 
1991;88(12):5252–5256.
  33.  Sozzani S, Introna M, Bernasconi S, et al. MCP-1 and CCR2 in HIV 
infection: regulation of agonist and receptor expression. J Leukoc Biol. 
1997;62(1):30–33.
  34.  Villiger PM, Terkeltaub R, Lotz M. Monocyte chemoattractant protein-1 
(MCP-1) expression in human articular cartilage. Induction by peptide 
regulatory factors and differential effects of dexamethasone and retinoic 
acid. J Clin Invest. 1992;90(2):488–496.
  35.  Kitchen SG, Korin YD, Roth MD, Landay A, Zack JA. Costimulation 
of naive CD8(+) lymphocytes induces CD4 expression and allows 
human immunodeficiency virus type 1 infection. J Virol. 1998;72(11): 
9054–9060.
  36.  Zloza A, Sullivan YB, Connick E, Landay AL, Al-Harthi L. CD8+ T cells 
that express CD4 on their surface (CD4dimCD8bright T cells) recognize 
an antigen-specific target, are detected in vivo, and can be productively 
infected by T-tropic HIV . Blood. 2003;102(6):2156–2164.
  37.  Ancuta P, Moses A, Gabuzda D. Transendothelial migration of CD16+ 
monocytes in response to fractalkine under constitutive and inflamma-
tory conditions. Immunobiology. 2004;209(1–2):11–20.HIV/AIDS - Research and Palliative Care 2010:2 47
Mechanisms of HIV-associated neurocognitive deficits Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  38.  Ancuta P, Wang J, Gabuzda D. CD16+ monocytes produce IL-6, CCL2, 
and matrix metalloproteinase-9 upon interaction with CX3CL1-express-
ing endothelial cells. J Leuko Biol. 2006;80(5):1156–1164.
  39.  Dhawan S, Weeks BS, Soderland C, et al. HIV-1 infection alters 
monocyte interactions with human microvascular endothelial cells. 
J Immunol. 1995;154(1):422–432.
  40.  Stent G, Crowe SM. Effects of HIV-1 on the surface expression of 
LFA-1 on cultured monocytes. J Acquir Immune Defic Syndr Hum 
Retrovirol. 1997;15(2):95–103.
  41.  Nottet HS, Persidsky Y, Sasseville VG, et al. Mechanisms for the 
transendothelial migration of HIV-1-infected monocytes into brain. 
J Immunol. 1996;156(3):1284–1295.
  42.  Seilhean D, Dzia-Lepfoundzou A, Sazdovitch V, et al. Astrocytic 
adhesion molecules are increased in HIV-1-associated cognitive/motor 
complex. Neuropathol Appl Neurobiol. 1997;23(2):83–92.
  43.  Eugenin EA, Gamss R, Buckner C, et al. Shedding of PECAM-1 during 
HIV infection: a potential role for soluble PECAM-1 in the pathogenesis 
of NeuroAIDS. J Leukoc Biol. 2006;79(3):444–452.
  44.  Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is 
required for transendothelial migration of leukocytes. J Exp Med. 
1993;178(2):449–460.
  45.  Losy J, Niezgoda A, Wender M. Increased serum levels of soluble 
PECAM-1 in multiple sclerosis patients with brain gadolinium-
enhancing lesions. J Neuroimmunol. 1999;99(2):169–172.
  46.  LaBranche CC, Hoffman TL, Romano J, et al. Determinants of CD4 
independence for a human immunodeficiency virus type 1 variant 
map outside regions required for coreceptor specificity. J Virol. 
1999;73(12):10310–10319.
  47.  Aggoun-Zouaoui D, Charriaut-Marlangue C, Rivera S, Jorquera I, 
Ben-Ari Y, Represa A. The HIV-1 envelope protein gp120 induces 
neuronal apoptosis in hippocampal slices. Neuroreport. 1996;7(2): 
433–436.
  48.  Meucci O, Miller RJ. gp120-induced neurotoxicity in hippocampal 
pyramidal neuron cultures: protective action of TGF-beta1. J Neurosci. 
1996;16(13):4080–4088.
  49.  Ohagen A, Devitt A, Kunstman KJ, et al. Genetic and functional 
analysis of full-length human immunodeficiency virus type 1 env genes 
derived from brain and blood of patients with AIDS. Journal Virol. 
2003;77(22):12336–12345.
  50.  Ohagen A, Ghosh S, He J, et al. Apoptosis induced by infection of primary 
brain cultures with diverse human immunodeficiency virus type 1 isolates: 
evidence for a role of the envelope. J Virol. 1999;73(2):897–906.
  51.  Power C, McArthur JC, Johnson RT, et al. Demented and nondemented 
patients with AIDS differ in brain-derived human immunodeficiency 
virus type 1 envelope sequences. J Virol. 1994;68(7):4643–4649.
  52.  Power C, McArthur JC, Nath A, et al. Neuronal death induced by 
brain-derived human immunodeficiency virus type 1 envelope genes 
differs between demented and nondemented AIDS patients. J Virol. 
1998;72(11):9045–9053.
  53.  Van Marle G, Rourke SB, Zhang K, et al. HIV dementia patients exhibit 
reduced viral neutralization and increased envelope sequence diversity in 
blood and brain. AIDS (London, England). 2002;16(14):1905–1914.
  54.  Jones MV, Bell JE, Nath A. Immunolocalization of HIV envelope 
gp120 in HIV encephalitis with dementia. AIDS (London, England). 
2000;14(17):2709–2713.
  55.  Gorry PR, Dunfee RL, Mefford ME, et al. Changes in the V3 region of 
gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate 
from a CCR5 Delta32 heterozygote. Virology. 2007;362(1):163–178.
  56.  Dunfee RL, Thomas ER, Wang J, Kunstman K, Wolinsky SM, Gabuzda 
D. Loss of the N-linked glycosylation site at position 386 in the HIV 
envelope V4 region enhances macrophage tropism and is associated 
with dementia. Virology. 2007;367(1):222–234.
  57.  Corasaniti MT, Bagetta G, Rotiroti D, Nistico G. The HIV envelope 
protein gp120 in the nervous system: interactions with nitric oxide, 
interleukin-1beta and nerve growth factor signalling, with pathologi-
cal implications in vivo and in vitro. Biochem Pharmacol. 1998;56(2): 
153–156.
  58.  Lee C, Tomkowicz B, Freedman BD, Collman RG. HIV-1 gp120-induced 
TNF-{alpha} production by primary human macrophages is mediated 
by phosphatidylinositol-3 (PI-3) kinase and mitogen-activated protein 
(MAP) kinase pathways. J Leukoc Biol. 2005;78(4):1016–1023.
  59.  Fantuzzi L, Canini I, Belardelli F, Gessani S. HIV-1 gp120 stimulates 
the production of beta-chemokines in human peripheral blood mono-
cytes through a CD4-independent mechanism. J Immunol. 2001;166(9): 
5381–5387.
  60.  D’Aversa TG, Eugenin EA, Berman JW. NeuroAIDS: contributions of 
the human immunodeficiency virus-1 proteins Tat and gp120 as well as 
CD40 to microglial activation. J Neurosci Res. 2005;81(3):436–446.
  61.  Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat 
protein exits from cells via a leaderless secretory pathway and binds to 
extracellular matrix-associated heparan sulfate proteoglycans through 
its basic region. AIDS (London, England). 1997;11(12):1421–1431.
  62.  Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat 
protein of HIV-1 stimulates growth of cells derived from Kaposi’s 
sarcoma lesions of AIDS patients. Nature. 1990;345(6270):84–86.
  63.  Ensoli B, Buonaguro L, Barillari G, et al. Release, uptake, and effects 
of extracellular human immunodeficiency virus type 1 Tat protein on 
cell growth and viral transactivation. J Virol. 1993;67(1):277–287.
  64.  Frankel AD, Pabo CO. Cellular uptake of the tat protein from human 
immunodeficiency virus. Cell. 1988;55(6):1189–1193.
  65.  Hudson L, Liu J, Nath A, et al. Detection of the human immunode-
ficiency virus regulatory protein tat in CNS tissues. J Neurovirol. 
2000;6(2):145–155.
  66.  Wieland U, Kuhn JE, Jassoy C, Rubsamen-Waigmann H, Wolber V , 
Braun RW. Antibodies to recombinant HIV-1 vif, tat, and nef proteins 
in human sera. Med Microbiol Immunol. 1990;179(1):1–11.
  67.  Westendorp MO, Frank R, Ochsenbauer C, et al. Sensitization of 
T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature. 
1995;375(6531):497–500.
  68.  Vogel BE, Lee SJ, Hildebrand A, et al. A novel integrin specificity exem-
plified by binding of the alpha v beta 5 integrin to the basic domain of the 
HIV Tat protein and vitronectin. J Cell Biol. 1993;121(2):461–468.
  69.  Albini A, Soldi R, Giunciuglio D, et al. The angiogenesis induced by 
HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular 
endothelial cells. Nat Med. 1996;2(12):1371–1375.
  70.  Liu Y, Jones M, Hingtgen CM, et al. Uptake of HIV-1 tat protein 
mediated by low-density lipoprotein receptor-related protein disrupts 
the neuronal metabolic balance of the receptor ligands. Nat Med. 
2000;6(12):1380–1387.
  71.  Pu H, Tian J, Flora G, et al. HIV-1 Tat protein upregulates inflamma-
tory mediators and induces monocyte invasion into the brain. Mol Cell 
Neurosci. 2003;24(1):224–237.
  72.  King JE, Eugenin EA, Buckner CM, Berman JW. HIV tat and neuro-
toxicity. Microbes Infect. 2006;8(5):1347–1357.
  73.  Rappaport J, Joseph J, Croul S, et al. Molecular pathway involved in 
HIV-1-induced CNS pathology: role of viral regulatory protein, Tat. 
J Leukoc Biol. 1999;65(4):458–465.
  74.  Jones M, Olafson K, Del Bigio MR, Peeling J, Nath A. Intraventricular 
injection of human immunodeficiency virus type 1 (HIV-1) tat protein 
causes inflammation, gliosis, apoptosis, and ventricular enlargement. 
J Neuropathol Exp Neurol. 1998;57(6):563–570.
  75.  Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, Nath A. 
Human immunodeficiency virus type 1 tat activates non-N-methyl-D-
aspartate excitatory amino acid receptors and causes neurotoxicity. Ann 
Neurol. 1995;37(3):373–380.
  76.  Nath A, Psooy K, Martin C, et al. Identification of a human immunode-
ficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. 
J Virol. 1996;70(3):1475–1480.
  77.  New DR, Ma M, Epstein LG, Nath A, Gelbard HA. Human immunode-
ficiency virus type 1 Tat protein induces death by apoptosis in primary 
human neuron cultures. J Neurovirol. 1997;3(2):168–173.
  78.  Sabatier JM, Vives E, Mabrouk K, et al. Evidence for neurotoxic 
activity of tat from human immunodeficiency virus type 1. J Virol. 
1991;65(2):961–967.HIV/AIDS - Research and Palliative Care 2010:2 48
Hazleton et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  79.  Shi B, Raina J, Lorenzo A, Busciglio J, Gabuzda D. Neuronal apoptosis 
induced by HIV-1 Tat protein and TNF-alpha: potentiation of neurotox-
icity mediated by oxidative stress and implications for HIV-1 dementia. 
J Neurovirol. 1998;4(3):281–290.
  80.  Strijbos PJ, Zamani MR, Rothwell NJ, Arbuthnott G, Harkiss G. Neuro-
toxic mechanisms of transactivating protein Tat of Maedi-Visna virus. 
Neurosci Lett. 1995;197(3):215–218.
  81.  Weeks BS, Lieberman DM, Johnson B, et al. Neurotoxicity of the 
human immunodeficiency virus type 1 tat transactivator to PC12 cells 
requires the Tat amino acid 49–58 basic domain. J Neurosci Res. 
1995;42(1):34–40.
  82.  Eugenin EA, D’Aversa TG, Lopez L, Calderon TM, Berman JW. 
MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or 
HIV-tat-induced apoptosis. J Neurochem. 2003;85(5):1299–1311.
  83.  Eugenin EA, King JE, Nath A, et al. HIV-tat induces formation of 
an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis 
in neurons and astrocytes. Proc Natl Acad Sci U S A. 2007;104(9): 
3438–3443.
  84.  Wang P, Barks JD, Silverstein FS. Tat, a human immunodeficiency 
virus-1-derived protein, augments excitotoxic hippocampal injury in 
neonatal rats. Neuroscience. 1999;88(2):585–597.
  85.  Haughey NJ, Nath A, Mattson MP, Slevin JT, Geiger JD. HIV-1 Tat 
through phosphorylation of NMDA receptors potentiates glutamate 
excitotoxicity. J Neurochem. 2001;78(3):457–467.
  86.  Bonavia R, Bajetto A, Barbero S, Albini A, Noonan DM, Schet-
tini G. HIV-1 Tat causes apoptotic death and calcium homeostasis 
alterations in rat neurons. Biochem Biophys Res Commun. 2001;288(2): 
301–308.
  87.  Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: 
high-avidity binding to beta-amyloid and increased frequency of type 
4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U 
S A. 1993;90(5):1977–1981.
  88.  Slooter AJ, Tang MX, van Duijn CM, et al. Apolipoprotein E epsilon4 
and the risk of dementia with stroke. A population-based investigation. 
J Amer Med Assoc. 1997;277(10):818–821.
  89.  Alberts MJ, Graffagnino C, McClenny C, et al. ApoE genotype 
and survival from intracerebral haemorrhage. Lancet. 1995; 
346(8974):575.
  90.  Tardiff BE, Newman MF, Saunders AM, et al. Preliminary report 
of a genetic basis for cognitive decline after cardiac operations. The 
Neurologic Outcome Research Group of the Duke Heart Center. Ann 
Thorac Surg. 1997;64(3):715–720.
  91.  Corder EH, Lannfelt L, Bogdanovic N, Fratiglioni L, Mori H. The role 
of APOE polymorphisms in late-onset dementias. Cell Mol Life Sci. 
1998;54(9):928–934.
  92.  Burt TD, Agan BK, Marconi VC, et al. Apolipoprotein (apo) E4 
enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 
genotype accelerates HIV disease progression. Proc Natl Acad Sci 
U S A. 2008;105(25):8718–8723.
  93.  Sharief MK, Ciardi M, Thompson EJ, et al. Tumour necrosis factor-
alpha mediates blood–brain barrier damage in HIV-1 infection of the 
central nervous system. Mediators Inflamm. 1992;1(3):191–196.
  94.  Achim CL, Heyes MP, Wiley CA. Quantitation of human immunode-
ficiency virus, immune activation factors, and quinolinic acid in AIDS 
brains. J Clin Invest. 1993;91(6):2769–2775.
  95.  Perrella O, Guerriero M, Izzo E, Soscia M, Carrieri PB. Interleukin-6 
and granulocyte macrophage-CSF in the cerebrospinal fluid from HIV 
infected subjects with involvement of the central nervous system. 
Arquivos de neuro-psiquiatria. 1992;50(2):180–182.
  96.  Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. 
Nat Rev Immunol. 2005;5(1):69–81.
  97.  Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-
1 replication in latently infected CD4+ T cells using a combination of 
cytokines. J Exp Med. 1998;188(1):83–91.
  98.  Sriram K, O’Callaghan JP. Divergent roles for tumor necrosis 
factor-alpha in the brain. J Neuroimmune Pharmacol. 2007;2(2): 
140–153.
  99.  Eugenin EA, Gaskill PJ, Berman JW. Tunneling nanotubes (TNT) are 
induced by HIV-infection of macrophages: a potential mechanism for 
intercellular HIV trafficking. Cell Immunol. 2009;254(2):142–148.
  100.  Eugenin EA, Gaskill PJ, Berman JW. Tunneling nanotubes (TNT): 
A potential mechanism for intercellular HIV trafficking. Communica-
tive and Integrative Biology. 2009;2(3):243–244.
  101.  Gerdes HH, Bukoreshtliev NV, Barroso JF. Tunneling nanotubes: 
a new route for the exchange of components between animal cells. 
FEBS Letters. 2007;581(11):2194–2201.
  102.  Onfelt B, Davis DM. Can membrane nanotubes facilitate communi-
cation between immune cells? Biochem Soc Trans. 2004;32(Pt 5): 
676–678.
  103.  Onfelt B, Purbhoo MA, Nedvetzki S, Sowinski S, Davis DM. Long-
distance calls between cells connected by tunneling nanotubules. Sci 
STKE. 2005;2005(313):pe55.
  104.  Rustom A, Saffrich R, Markovic I, Walther P, Gerdes HH. Nanotubular 
highways for intercellular organelle transport. Science (New York, N.) 
2004;303(5660):1007–1010.
  105.  Saez JC, Berthoud VM, Branes MC, Martinez AD, Beyer EC. Plasma 
membrane channels formed by connexins: their regulation and func-
tions. Physiol Rev. 2003;83(4):1359–1400.
  106.  Willecke K, Eiberger J, Degen J, et al. Structural and functional 
diversity of connexin genes in the mouse and human genome. Biol 
Chem. 2002;383(5):725–737.
  107.  Bennett MV , Rubin JB, Bargiello TA, Verselis VK. Structure-function 
studies of voltage sensitivity of connexins, the family of gap junction 
forming proteins. Jpn J Physiol. 1993;43 Suppl 1:S301–S310.
  108.  Harris AL, Bevans CG. Exploring hemichannel permeability in vitro. 
Methods Mol Biol. 2001;154:357–377.
  109.  Bennett MV , Zukin RS. Electrical coupling and neuronal synchroniza-
tion in the Mammalian brain. Neuron. 2004;41(4):495–511.
  110.  Rouach N, Avignone E, Meme W, et al. Gap junctions and connexin 
expression in the normal and pathological central nervous system. 
Biol Cell. 2002;94(7–8):457–475.
  111.  Kielian T, Esen N. Effects of neuroinflammation on glia-glia gap 
junctional intercellular communication: a perspective. Neurochem 
Int. 2004;45(2–3):429–436.
  112.  Eugenin EA, Branes MC, Berman JW, Saez JC. TNF-alpha plus IFN-
gamma induce connexin43 expression and formation of gap junctions 
between human monocytes/macrophages that enhance physiological 
responses. J Immunol. 2003;170(3):1320–1328.
  113.  El-Sabban ME, Merhi RA, Haidar HA, et al. Human T-cell lym-
photropic virus type 1-transformed cells induce angiogenesis and 
establish functional gap junctions with endothelial cells. Blood. 
2002;99(9):3383–3389.
  114.  Onfelt B, Nedvetzki S, Benninger RK, et al. Structurally distinct mem-
brane nanotubes between human macrophages support long-distance 
vesicular traffic or surfing of bacteria. J Immunol. 2006;177(12): 
8476–8483.
  115.  Onfelt B, Nedvetzki S, Yanagi K, Davis DM. Cutting edge: Mem-
brane nanotubes connect immune cells. J Immunol. 2004;173(3): 
1511–1513.
  116.  Magalhaes AC, Baron GS, Lee KS, et al. Uptake and neuritic transport 
of scrapie prion protein coincident with infection of neuronal cells. 
J Neurosci. 2005;25(21):5207–5216.
  117.  Watkins SC, Salter RD. Functional connectivity between immune cells 
mediated by tunneling nanotubules. Immunity. 2005;23(3):309–318.
  118.  Sherer NM, Lehmann MJ, Jimenez-Soto LF, Horensavitz C, Pypaert M, 
Mothes W. Retroviruses can establish filopodial bridges for efficient 
cell-to-cell transmission. Nat Cell Biol. 2007;9(3):310–315.
  119.  Hase K, Kimura S, Takatsu H, et al. M-Sec promotes membrane 
nanotube formation by interacting with Ral and the exocyst complex. 
Nat Cell Biol. 2009;11(12):1427–1432.
  120.  Xu W, Santini PA, Sullivan JS, et al. HIV-1 evades virus-specific 
IgG2 and IgA responses by targeting systemic and intestinal B cells 
via long-range intercellular conduits. Nat Immunol. 2009;10(9): 
1008–1017.HIV/AIDS - Research and Palliative Care 2010:2
HIV/AIDS - Research and Palliative Care
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/hivaids---research-and-palliative-care-journal
HIV/AIDS - Research and Palliative Care is an international, peer-
reviewed open-access journal focusing on advances in research in 
HIV, its clinical progression and management options including anti-
viral treatment, palliative care and public healthcare policies to control 
viral spread. The journal welcomes original research, basic science, 
clinical & epidemiological studies, reviews & evaluations, expert 
opinion & commentary, case reports & extended reports. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
49
Mechanisms of HIV-associated neurocognitive deficits Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
  121.  Dou H, Grotepas CB, McMillan JM, et al. Macrophage delivery of 
nanoformulated antiretroviral drug to the brain in a murine model of 
neuroAIDS. J Immunol. 2009;183(1):661–669.
  122.  Dou H, Morehead J, Destache CJ, et al. Laboratory investigations for 
the morphologic, pharmacokinetic, and anti-retroviral properties of 
indinavir nanoparticles in human monocyte-derived macrophages. 
Virology. 2007;358(1):148–158.
  123.  Hanson LR, Frey WH 2nd. Strategies for intranasal delivery of thera-
peutics for the prevention and treatment of neuroAIDS. J Neuroim-
mune Pharmacol. 2007;2(1):81–86.
  124.  Ansari KS, Yu PH, Kruck TP, Tatton WG. Rescue of axotomized 
immature rat facial motoneurons by R(-)-deprenyl: stereospecificity 
and independence from monoamine oxidase inhibition. J Neurosci. 
1993;13(9):4042–4053.
  125.  Carrillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K, Ivy GO. (–) 
Deprenyl increases activities of superoxide dismutase and catalase in cer-
tain brain regions in old male mice. Life Sci. 1994;54(14):975–981.
  126.  Matsui Y, Kumagae Y. Monoamine oxidase inhibitors prevent striatal 
neuronal necrosis induced by transient forebrain ischemia. Neurosci 
Lett. 1991;126(2):175–178.
  127.  Salo PT, Tatton WG. Deprenyl reduces the death of motoneurons 
caused by axotomy. J Neurosci Res. 1992;31(2):394–400.
  128.  Tatton WG, Greenwood CE. Rescue of dying neurons: a new action 
for deprenyl in MPTP parkinsonism. J Neurosci Res. 1991;30(4): 
666–672.
  129.  A randomized, double-blind, placebo-controlled trial of deprenyl and 
thioctic acid in human immunodeficiency virus-associated cognitive 
impairment. Dana Consortium on the Therapy of HIV Dementia and 
Related Cognitive Disorders. Neurology. 1998;50(3):645–651.
  130.  Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, 
Kieburtz K. Transdermal selegiline in HIV-associated cognitive 
impairment: pilot, placebo-controlled study. Neurology. 2000;54(1): 
233–235.
  131.  Schifitto G, Yiannoutsos CT, Ernst T, et al. Selegiline and oxidative 
stress in HIV-associated cognitive impairment. Neurology. 2009.
  132.  Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegi-
line transdermal system for HIV-associated cognitive impairment. 
Neurology. 2007;69(13):1314–1321.
  133.  Agrawal L, Louboutin JP, Reyes BA, Van Bockstaele EJ, Strayer 
DS. Antioxidant enzyme gene delivery to protect from HIV-1 gp120-
induced neuronal apoptosis. Gene Ther. 2006;13(23):1645–1656.
  134.  Louboutin JP, Agrawal L, Reyes BA, Van Bockstaele EJ, Strayer DS. 
Protecting neurons from HIV-1 gp120-induced oxidant stress using 
both localized intracerebral and generalized intraventricular admin-
istration of antioxidant enzymes delivered by SV40-derived vectors. 
Gene Ther. 2007;14(23):1650–1661.
  135.  Louboutin JP, Agrawal L, Reyes BA, Van Bockstaele EJ, Strayer DS. 
HIV-1 gp120 neurotoxicity proximally and at a distance from the point 
of exposure: protection by rSV40 delivery of antioxidant enzymes. 
Neurobiol Dis. 2009;34(3):462–476.
  136.  Agrawal L, Louboutin JP, Strayer DS. Preventing HIV-1 Tat-induced 
neuronal apoptosis using antioxidant enzymes: mechanistic and 
  therapeutic implications. Virology. 2007;363(2):462–472.
  137.  Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties 
and their clinical implications. J Am Acad Dermatol. 2006;54(2): 
258–265.
  138.  Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC. Minocycline for 
short-term neuroprotection. Pharmacotherapy. 2006;26(4):515–521.
  139.  Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline 
as a neuroprotective agent. Neuroscientist. 2005;11(4):308–322.
  140.  Follstaedt SC, Barber SA, Zink MC. Mechanisms of minocycline-
induced suppression of simian immunodeficiency virus encephalitis: 
inhibition of apoptosis signal-regulating kinase 1. J Neurovirol. 
2008;14(5):376–388.
  141.  Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human 
immunodeficiency virus activity of minocycline. J Amer Med Assoc. 
2005;293(16):2003–2011.
  142.  Lipton SA. Paradigm shift in neuroprotection by NMDA recep-
tor blockade: memantine and beyond. Nat Rev Drug Discov. 
2006;5(2):160–170.
  143.  Fleischhacker WW, Buchgeher A, Schubert H. Memantine in the 
treatment of senile dementia of the Alzheimer type. Prog Neuropsy-
chopharmacol Biol Psychiatry. 1986;10(1):87–93.
  144.  Winblad B, Poritis N. Memantine in severe dementia: results of 
the 9M-Best Study (Benefit and efficacy in severely demented 
patients during treatment with memantine). Int J Geriatr Psych. 
1999;14(2):135–146.
  145.  Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an 
NMDA receptor antagonist, in the treatment of Parkinson’s disease. 
J Neural Transm. 1992;4:277–282.
  146.  Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. 
Memantine in moderate-to-severe Alzheimer’s disease. New Engl J 
Med. 2003;348(14):1333–1341.
  147.  Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, 
Gergel I. Memantine treatment in patients with moderate to severe 
Alzheimer disease already receiving donepezil: a randomized con-
trolled trial. J Amer Med Assoc. 2004;291(3):317–324.
  148.  Toggas SM, Masliah E, Mucke L. Prevention of HIV-1 gp120-induced 
neuronal damage in the central nervous system of transgenic mice 
by the NMDA receptor antagonist memantine. Brain Research. 
1996;706(2):303–307.
  149.  Lipton SA. Memantine prevents HIV coat protein-induced neuronal 
injury in vitro. Neurology. 1992;42(7):1403–1405.
  150.  Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD. Syner-
gistic neurotoxicity by human immunodeficiency virus proteins Tat and 
gp120: protection by memantine. Ann Neurol. 2000;47(2):186–194.
  151.  Anderson ER, Gendelman HE, Xiong H. Memantine protects hippo-
campal neuronal function in murine human immunodeficiency virus 
type 1 encephalitis. J Neurosci. 2004;24(32):7194–7198.
  152.  Schifitto G, Navia BA, Yiannoutsos CT, et al. Memantine and HIV-
associated cognitive impairment: a neuropsychological and proton 
magnetic resonance spectroscopy study. AIDS (London, England). 
2007;21(14):1877–1886.